Arcus Biosciences Quick Ratio 2017-2022 | RCUS

Historical quick ratio values for Arcus Biosciences (RCUS) over the last 10 years.
Arcus Biosciences Quick Ratio Historical Data
Date Current Assets - Inventory Current Liabilities Quick Ratio
2022-12-31 $0.00B $0.19B 0.00
2022-09-30 $0.00B $0.18B 0.00
2022-06-30 $0.00B $0.16B 0.00
2022-03-31 $0.00B $0.16B 0.00
2021-12-31 $0.00B $0.17B 0.00
2021-09-30 $0.00B $0.14B 0.00
2021-06-30 $0.00B $0.13B 0.00
2021-03-31 $0.00B $0.13B 0.00
2020-12-31 $0.00B $0.12B 0.00
2020-09-30 $0.00B $0.16B 0.00
2020-06-30 $0.00B $0.04B 0.00
2020-03-31 $0.00B $0.02B 0.00
2019-12-31 $0.00B $0.02B 0.00
2019-09-30 $0.00B $0.02B 0.00
2019-06-30 $0.00B $0.03B 0.00
2019-03-31 $0.00B $0.02B 0.00
2018-12-31 $0.00B $0.02B 0.00
2018-09-30 $0.00B $0.02B 0.00
2018-06-30 $0.00B $0.02B 0.00
2018-03-31 $0.00B $0.01B 0.00
2017-12-31 $0.00B $0.01B 0.00
2017-09-30 $0.00B 0.00
2017-06-30 $0.00B 0.00
2017-03-31 $0.00B 0.00
2016-12-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.194B $0.112B
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $140.576B 8.70
GSK (GSK) United Kingdom $75.923B 9.52
Bio-Rad Laboratories (BIO.B) United States $13.735B 32.61
QIAGEN (QGEN) Netherlands $10.436B 19.34
Ginkgo Bioworks Holdings (DNA) United States $2.549B 0.00
Biohaven (BHVN) United States $0.913B 0.00
Emergent Biosolutions (EBS) United States $0.394B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.152B 0.00
Enzo Biochem (ENZ) United States $0.106B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.012B 0.00